Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo” or the "Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ...

and other risks detailed in Repligen's filings with the U.S. Securities and Exchange Commission (the Commission), including Annual Report on Form 10-K for the year ended December 31, 2023 and in ...

Donald Trump’s election win means the almost certain end of Gary Gensler’s leadership of the Securities and Exchange ...